A DNA methylation‐based definition of biologically distinct breast cancer subtypes

In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation‐based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17 normal breast samples, together with DNA copy number changes and subtype‐specific markers by tissue microarrays. The identified methylation signatures were validated against a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50 method (The Cancer Genome Atlas). Selected markers were pyrosequenced in an independent validation cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The results demonstrate that DNA methylation patterns linked to the luminal‐B subtype are characterized by CpG island promoter methylation events. In contrast, a large fraction of basal‐like tumors are characterized by hypomethylation events occurring within the gene body. Based on these hallmark signatures, we defined two DNA methylation‐based subtypes, Epi‐LumB and Epi‐Basal, and show that they are associated with unfavorable clinical parameters and reduced survival. Our data show that distinct mechanisms leading to changes in CpG methylation states are operative in different breast cancer subtypes. Importantly, we show that a few selected proxy markers can be used to detect the distinct DNA methylation‐based subtypes thereby providing valuable information on disease prognosis.

[1]  L. Saal,et al.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.

[2]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[3]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[4]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[6]  Gangning Liang,et al.  Gene body methylation can alter gene expression and is a therapeutic target in cancer. , 2014, Cancer cell.

[7]  I. Ng,et al.  Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function , 2009, PloS one.

[8]  Benjamin Haibe-Kains,et al.  DNA methylation profiling reveals a predominant immune component in breast cancers , 2011, EMBO molecular medicine.

[9]  Zhongming Zhao,et al.  TSGene: a web resource for tumor suppressor genes , 2012, Nucleic Acids Res..

[10]  Timothy E. Reddy,et al.  Dynamic DNA methylation across diverse human cell lines and tissues , 2013, Genome research.

[11]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[12]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[14]  M. C. Cabrera,et al.  BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. , 2010, Breast disease.

[15]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Charles M Perou,et al.  Systems biology and genomics of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[17]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[18]  P. Marker.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007 .

[19]  Miguel Martín,et al.  Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer , 2009, Breast Cancer Research.

[20]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[21]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[22]  M. Fraga,et al.  DNA methylation epigenotypes in breast cancer molecular subtypes , 2010, Breast Cancer Research.

[23]  L. Tryggvadottir,et al.  Data quality at the Icelandic Cancer Registry: Comparability, validity, timeliness and completeness , 2012, Acta oncologica.

[24]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[25]  Johan Staaf,et al.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns , 2010, Breast Cancer Research.

[26]  P. Tonin,et al.  An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer , 2012, Oncogene.

[27]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[28]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[29]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[30]  Manel Esteller,et al.  Epigenetic modifications in breast cancer and their role in personalized medicine. , 2013, The American journal of pathology.

[31]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[32]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.